Donaperminogene seltoplasmid (ViroMed), also referred to as VM202, is a DNA-based drug that is designed to produce two isoforms of HGF (hepatocyte growth factor), HGF728 and HGF723. When VM202 is delivered to the affected area by a single intramuscular injection, the drug enters a small portion of the surrounding muscle cells. These cells simultaneously produce the two isoforms of the HGF proteins, which are subsequently secreted and bound to the cellular receptor called c-Met present on the surface of neighboring endothelial, smooth muscle, or neuronal cells. In the case of painful diabetic peripheral neuropathy, microvasculature is restored, allowing the supply of oxygen and nutrients to the nerve cells and the removal of toxic metabolites, and thereby aiding in survival of the nerves. HGF can also function as a neurotrophic factor leading to the creation of new nerve cells. Sympathetic neurons express both HGF and its cognate receptor. When VM202 is injected along sural, peroneal, and saphenous nerves and their branches, the localized production of HGF resulting from VM202 injection promotes the growth of sympathetic neurons, as well as axonal growth and regeneration.
LIST OF FIGURES
9 Figure 1: Donaperminogene seltoplasmid for neuropathic pain – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
13 Figure 4: Donaperminogene seltoplasmid sales for neuropathic pain in the US, 2017–26
LIST OF TABLES 6 Table 1: Donaperminogene seltoplasmid drug profile
7 Table 2: Donaperminogene seltoplasmid Phase II data in neuropathic pain
8 Table 3: Donaperminogene seltoplasmid Phase III trials in neuropathic pain
13 Table 4: Donaperminogene seltoplasmid sales for neuropathic pain in the US ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.